;
Skip to main content
Home > The Daily Extra > Company News

Chronological Index of : Company News

 Current Issue
  • COMPANY NEWS: Provenge bidding starts at $275M

    Roughly 4.5 years after boasting the first approved prostate cancer vaccine in the U.S. and a market cap north of $6.5 billion, Chapter 11 bankruptcy proceedings from Dendreon Corp. (NASDAQ:DNDN) start the bidding for …

    Published on 11/10/2014
  • COMPANY NEWS: FDA dings NDA for Avanir migraine therapy

    Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) said FDA is unlikely to approve AVP-825 by the migraine therapy's Nov. 25 PDUFA date. The company received a discipline review letter in which the agency questioned study data …

    Published on 11/7/2014
  • COMPANY NEWS: FDA panel backs Rockwell's Triferic

    Rockwell Medical Inc. (NASDAQ:RMTI) gained $1.22 (13%) to $10.55 on Friday after FDA's Oncologic Drugs Advisory Committee voted 8-3 that the benefits of Triferic soluble ferric pyrophosphate citrate outweigh the risks. …

    Published on 11/7/2014
  • COMPANY NEWS: Morning-after hangover for Salix

    Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) closed down $47.08 (34%) to $91.47 on Friday as investors digested Thursday's announcement that the specialty pharma's board had retained outside counsel to review the company's …

    Published on 11/7/2014
  • COMPANY NEWS: Aegerion buys Myalept from AZ for $325M

    Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) acquired global rights outside of three Asian territories to Myalept metreleptin from AstraZeneca plc (LSE:AZN; NYSE:AZN) for $325 million up front. The transaction is …

    Published on 11/6/2014
  • COMPANY NEWS: Breakthrough designation for Spark's SPK-RPE65

    FDA granted breakthrough therapy designation to SPK-RPE65 (AAV2-hRPE65v2) from Spark Therapeutics LLC (Philadelphia, Pa.) for the treatment of nyctalopia, or night blindness, in patients with Leber's congenital …

    Published on 11/6/2014
  • COMPANY NEWS: FDA panel rebuffs Novartis' panobinostat

    FDA's Oncologic Drugs Advisory Committee voted 5-2 that the progression-free survival (PFS) benefit of Farydak panobinostat (LBH589) from Novartis AG (NYSE:NVS; SIX:NOVN) does not outweigh its safety risks in …

    Published on 11/6/2014
  • COMPANY NEWS: FDA approves Olysio/Sovaldi combo for HCV

    FDA approved the combination of Olysio simeprevir from Johnson & Johnson (NYSE:JNJ) and Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) to treat chronic HCV genotype 1 infection. The combination is the second…

    Published on 11/5/2014
  • COMPANY NEWS: GSK submits mepolizumab for U.S., EU approval

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) submitted a BLA to FDA and an MAA to EMA for mepolizumab (SB-240563) as maintenance therapy for patients with severe eosinophilic asthma. The humanized IgG mAb against IL-5 is the…

    Published on 11/5/2014
  • COMPANY NEWS: Vertex submits NDA, MAA for Kalydeco/lumacaftor

    Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) submitted an NDA to FDA and an MAA to EMA for the combination of 250 mg Kalydeco ivacaftor and 400 mg lumacaftor (VX-809) to treat cystic fibrosis (CF) in patients ages 12 and …

    Published on 11/5/2014
  • COMPANY NEWS: After BMS deal, F-star launches second newco

    F-star Biotechnology Ltd. (Cambridge, U.K.) launched newco F-star Beta Ltd. (Cambridge, U.K.) and granted it licenses to develop antibody fragments and bispecific antibodies against certain oncology and immuno-oncology …

    Published on 11/4/2014
  • COMPANY NEWS: Astellas, Proteostasis to collaborate on UFP modulators

    Astellas Pharma Inc. (Tokyo:4503) and Proteostasis Therapeutics Inc. (Cambridge, Mass.) partnered to use Proteostasis' technologies to discover and develop candidates to modulate the unfolded protein response (UFP). …

    Published on 11/4/2014
  • COMPANY NEWS: FDA asks if panobinostat's PFS benefit outweighs risks

    FDA is asking its Oncologic Drugs Advisory Committee whether the progression-free survival (PFS) benefit of Farydak panobinostat (LBH589) from Novartis AG (NYSE:NVS; SIX:NOVN) outweighs safety risks in combination with …

    Published on 11/4/2014
  • COMPANY NEWS: Industry responds to Viehbacher's departure

    On the third-quarter earnings call of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), CEO Leonard Schleifer addressed the company's relationship with Sanofi (Euronext:SAN; NYSE:SNY) following the ouster of CEO Christopher…

    Published on 11/4/2014
  • COMPANY NEWS: MedImmune to acquire Definiens

    The MedImmune LLC unit of AstraZeneca plc (LSE:AZN; NYSE:AZN) will acquire Definiens AG (Munich, Germany) for $150 million up front plus potential milestones. MedImmune spokesperson Tracy Rossin said the company will …

    Published on 11/4/2014
  • COMPANY NEWS: Sandoz responds to Amgen

    A spokesperson for Sandoz told BioCentury the unit of Novartis AG (NYSE:NVS; SIX:NOVN) is unsurprised by a lawsuit and Citizen's Petition from Amgen Inc. (NASDAQ:AMGN) alleging the generics maker failed to properly …

    Published on 11/4/2014
  • COMPANY NEWS: BMS takes option to acquire Galecto

    Bristol-Myers Squibb Co. (NYSE:BMY) obtained an exclusive option to acquire Galecto Biotech AB (Copenhagen, Denmark), which would give it rights to lead program TD139, an inhaled galectin-3 (LGALS3) inhibitor to treat …

    Published on 11/3/2014
  • COMPANY NEWS: LabCorp acquiring Covance for $6.1B

    Diagnostics company Laboratory Corp. of America Holdings (NYSE:LH) has agreed to acquire contract research organization Covance Inc. (NYSE:CVD) for $6.1 billion, or $105.12 per share, a 32% premium to the CRO's closing …

    Published on 11/3/2014
  • COMPANY NEWS: AbbVie looking for specialty deals

    With 3Q14 earnings that beat guidance, AbbVie Inc. (NYSE:ABBV) CEO Richard Gonzalez said the pharma still has an appetite for M&A, but declared it's unlikely to find more $50 billion opportunities like the attempted …

    Published on 10/31/2014
  • COMPANY NEWS: Aegerion trips on Juxtapid shortfall

    Aegerion (NASDAQ:AEGR) plunged $14.02 (41%) to $20.19 on Friday as investors reponded to the company's FY14 guidance post-market on Thursday that fell short of expectations. Citing slower than expected growth and higher…

    Published on 10/31/2014
  • COMPANY NEWS: BMS and OliPass partner to develop PNA-based therapeutics

    Bristol-Myers Squibb Co. (NYSE:BMY) and OliPass Corp. (Suwon, South Korea) partnered to develop therapeutics against multiple targets using OliPass' peptide nucleic acid (PNA) technology platform. OliPass will receive …

    Published on 10/30/2014
  • COMPANY NEWS: FDA panel backs Daiichi's edoxaban

    FDA's Cardiovascular and Renal Drugs Advisory Committee voted 9-1 to recommend approval of Savaysa edoxaban from Daiichi Sankyo Co. Ltd. (Tokyo:4568) to prevent stroke and systemic embolism in patients with non-valvular…

    Published on 10/30/2014
  • COMPANY NEWS: FDA approves Pfizer's meningitis B vaccine

    FDA granted accelerated approval for Trumenba from Pfizer Inc. (NYSE:PFE) to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals aged 10-25. The bivalent meningococcal B …

    Published on 10/29/2014
  • COMPANY NEWS: Xencor revises XmAb5871 deal with Amgen

    Xencor Inc. (NASDAQ:XNCR) renegotiated its deal with Amgen Inc. (NASDAQ:AMGN) related to autoimmune candidate XmAb5871. Xencor terminated the companies' original deal in which the bellwether had an option to license …

    Published on 10/29/2014
  • COMPANY NEWS: Amgen committed to pipeline, not breakup

    Amgen Inc. (NASDAQ:AMGN) shares traded up $8.99 to $157.19 on Tuesday after it mapped out its growth strategy at its investor meeting and said it has no intention to break up.Amgen is under pressure from activist …

    Published on 10/28/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993